Motyan J, Miczi M, Tozser J
Int J Mol Sci. 2020; 21(4).
PMID: 32079302
PMC: 7072860.
DOI: 10.3390/ijms21041352.
Li M, Gustchina A, Cruz R, Simoes M, Curto P, Martinez J
Acta Crystallogr D Biol Crystallogr. 2015; 71(Pt 10):2109-18.
PMID: 26457434
PMC: 4601372.
DOI: 10.1107/S1399004715013905.
Jaskolski M, Miller M, Mohana Rao J, Gustchina A, Wlodawer A
FEBS J. 2015; 282(21):4059-66.
PMID: 26258480
PMC: 6310002.
DOI: 10.1111/febs.13397.
Serriere J, Robert X, Perez M, Gouet P, Guillon C
Retrovirology. 2013; 10:64.
PMID: 23800358
PMC: 3706335.
DOI: 10.1186/1742-4690-10-64.
Kenyon J, Lever A
Viruses. 2011; 3(11):2192-213.
PMID: 22163340
PMC: 3230847.
DOI: 10.3390/v3112192.
Comparative studies on retroviral proteases: substrate specificity.
Tozser J
Viruses. 2011; 2(1):147-165.
PMID: 21994605
PMC: 3185560.
DOI: 10.3390/v2010147.
Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.
Li M, Gustchina A, Matuz K, Tozser J, Namwong S, Goldfarb N
FEBS J. 2011; 278(22):4413-24.
PMID: 21951660
PMC: 3500906.
DOI: 10.1111/j.1742-4658.2011.08364.x.
Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease.
Lin Y, Perryman A, Olson A, Torbett B, Elder J, Stout C
Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 6):540-8.
PMID: 21636894
PMC: 3107052.
DOI: 10.1107/S0907444911011681.
Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease.
Lin Y, Torbett B, Elder J
J Virol. 2010; 84(13):6799-809.
PMID: 20410281
PMC: 2903298.
DOI: 10.1128/JVI.00294-10.
Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV.
Elder J, Lin Y, Fink E, Grant C
Curr HIV Res. 2010; 8(1):73-80.
PMID: 20210782
PMC: 2853889.
DOI: 10.2174/157016210790416389.
Molecular mechanisms of FIV infection.
Elder J, Sundstrom M, de Rozieres S, de Parseval A, Grant C, Lin Y
Vet Immunol Immunopathol. 2008; 123(1-2):3-13.
PMID: 18289701
PMC: 2409060.
DOI: 10.1016/j.vetimm.2008.01.007.
Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.
Heaslet H, Lin Y, Tam K, Torbett B, Elder J, Stout C
Retrovirology. 2007; 4:1.
PMID: 17212810
PMC: 1781954.
DOI: 10.1186/1742-4690-4-1.
Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
Lin Y, Brik A, de Parseval A, Tam K, Torbett B, Wong C
J Virol. 2006; 80(16):7832-43.
PMID: 16873240
PMC: 1563824.
DOI: 10.1128/JVI.00374-06.
Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design.
Li M, Laco G, Jaskolski M, Rozycki J, Alexandratos J, Wlodawer A
Proc Natl Acad Sci U S A. 2005; 102(51):18332-7.
PMID: 16352712
PMC: 1317974.
DOI: 10.1073/pnas.0509335102.
Assessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3.
de Rozieres S, Swan C, Sheeter D, Clingerman K, Lin Y, Huitron-Resendiz S
Retrovirology. 2004; 1:38.
PMID: 15555065
PMC: 535546.
DOI: 10.1186/1742-4690-1-38.
Inhibitor design by wrapping packing defects in HIV-1 proteins.
Fernandez A, Rogale K, Scott R, Scheraga H
Proc Natl Acad Sci U S A. 2004; 101(32):11640-5.
PMID: 15289598
PMC: 511032.
DOI: 10.1073/pnas.0404641101.
Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
Lin Y, Beck Z, Morris G, Olson A, Elder J
J Virol. 2003; 77(12):6589-600.
PMID: 12767979
PMC: 156162.
DOI: 10.1128/jvi.77.12.6589-6600.2003.
Retroviral proteases.
Dunn B, Goodenow M, Gustchina A, Wlodawer A
Genome Biol. 2002; 3(4):REVIEWS3006.
PMID: 11983066
PMC: 139352.
DOI: 10.1186/gb-2002-3-4-reviews3006.
Viral evolution in response to the broad-based retroviral protease inhibitor TL-3.
Buhler B, Lin Y, Morris G, Olson A, Wong C, Richman D
J Virol. 2001; 75(19):9502-8.
PMID: 11533212
PMC: 114517.
DOI: 10.1128/JVI.75.19.9502-9508.2001.
Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.
Beck Z, Lin Y, Elder J
J Virol. 2001; 75(19):9458-69.
PMID: 11533208
PMC: 114513.
DOI: 10.1128/JVI.75.19.9458-9469.2001.